Walach N, Guterman A, Rabinowitz H, Kaufman S, Habot B
Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel.
J Surg Oncol. 1991 Jan;46(1):37-9. doi: 10.1002/jso.2930460109.
Leukocyte alkaline phosphatase (LAP) activity in peripheral blood was determined in 54 patients with cerebrovascular disease (CVD), 11 patients with primary brain tumor, and 23 patients with metastatic brain tumor. The LAP score of the primary brain tumor patients (155 +/- 40) was significantly higher (P less than 0.03) than the LAP score for cerebrovascular disease patients (96 +/- 87). The LAP score levels of the metastatic brain tumor patients (251 +/- 55) was significantly higher as compared with both the cerebrovascular disease (P less than 0.001) and primary brain tumor groups (P less than 0.001). The LAP score could serve as an additional, although non-specific, marker to assist in the differentiation between cerebrovascular disease and brain tumors.
对54例脑血管疾病（CVD）患者、11例原发性脑肿瘤患者和23例转移性脑肿瘤患者的外周血白细胞碱性磷酸酶（LAP）活性进行了测定。原发性脑肿瘤患者的LAP评分（155±40）显著高于脑血管疾病患者的LAP评分（96±87）（P＜0.03）。转移性脑肿瘤患者的LAP评分水平（251±55）与脑血管疾病组（P＜0.001）和原发性脑肿瘤组（P＜0.001）相比均显著更高。LAP评分可作为一种辅助手段，尽管是非特异性的，以帮助区分脑血管疾病和脑肿瘤。
